Investigational drug · Phase 2
GFH925
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advance Non-small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "GFH925"
First trial start
2023
Apr 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GFH925", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advance Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "GFH925" as an intervention, largest first.
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05005234 · 334 participants · Start Sep 13, 2021 · Primary completion Feb 20, 2023
Drug: GFH925 · For: KRAS G12C
Sites: Guangzhou, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05504278 · 144 participants (planned) · Start Sep 20, 2022 · Primary completion May 31, 2025
Drug: IBI351; Cetuximab and 4 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Jilin City, China
Genfleet Therapeutics (Shanghai) Inc.Industry
NCT05756153 · 47 participants · Start Apr 25, 2023 · Primary completion Apr 30, 2025
Drug: GFH925; Cetuximab · For: Advance Non-small Cell Lung Cancer
Sites: Athens, Greece; Thessaloniki, Greece; Bologna, Italy · 21 sites in all
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05497336 · 8 participants · Start Aug 18, 2022 · Primary completion Jan 24, 2025
Drug: IBI351; Cetuximab · For: Colorectal Cancer
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors.
Jiang T, Lin C, Le S, et al. · J Med Chem 2025
- Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.
Yuan Y, Deng Y, Jin Y, et al. · Signal Transduct Target Ther 2025
- Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
Zhou Q, Meng X, Sun L, et al. · J Thorac Oncol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.